Heidi Health raises $340 million to expand its AI medical scribe -- and the round's own headline number depends on which country's dollar you're reading

Heidi Health, the Melbourne-founded startup building what it calls an "AI Care Partner" for clinicians, raised $340 million this week in a round that combines two very different kinds of capital: $100 million in Series C equity led by Blackbird, with Phoenix Court, Point72 Private Investments and Headline participating, and $240 million from General Catalyst's Customer Value Fund -- a revenue-linked financing instrument, not a straight equity check, earmarked specifically to fund Heidi's sales and marketing expansion. The company's core product listens to a patient visit, drafts the clinical note, and suggests billing codes; a clinician reviews and signs off before anything enters the record. Heidi says the platform has now been used across more than 175 million patient visits in 110 languages. The product line has grown well past a single scribing tool: alongside the core Scribe, Heidi now sells Evidence (the research-summary tool), Remote (wearable hardware for capturing vitals in clinical settings) and Dictate (standalone voice-to-text) as a bundled suite aimed at health systems rather than individual clinicians.

The round's headline valuation is where the coverage splits, and not because anyone is disputing the underlying deal. Bloomberg, reporting through Investing.com, puts the new valuation at $900 million, explicitly in US dollars -- roughly double Heidi's prior round. SmartCompany, an Australian outlet, reported the same week that Heidi "raised $475 million" at a "$1.26 billion" valuation, with no currency specified anywhere in the piece. The gap is too clean to be a real disagreement: A$1.26 billion converts to roughly $850-900 million US at prevailing exchange rates -- squarely in line with Bloomberg's figure -- and Heidi's own US-based new investors, General Catalyst and Point72 among them, report and fundraise in dollars. Read together, this looks like one funding event described twice in two currencies, not two different rounds.

Growth is the part of the story with the least ambiguity. Heidi's annual recurring revenue hit $50 million in April, up from roughly $1 million about two years earlier, according to Bloomberg's reporting -- and the company says its Evidence feature, a separate tool that returns research summaries with citations and a risk score, has answered more than 10 million queries since its March launch. Heidi's enterprise customers now include Beth Israel Lahey Health in Massachusetts and NHS England Midlands, where Heidi was selected as sole supplier. The company plans to add roughly 150 staff over the next year, growing from close to 600 today. Total funding to date now stands above $430 million across every round since Heidi's 2023 Series A, which raised $10 million -- a trajectory that puts this week's round at roughly 34 times the company's earliest institutional check in just over three years.

What Heidi's product actually does -- and doesn't do -- matters more than the funding math. Heidi is registered as an MHRA Class I medical device in the UK for its summarization function, and the company publishes its own safety guidance stating plainly that clinicians retain full responsibility for note accuracy and that the underlying language model "can hallucinate." An independent review of that guidance for clinicians, published by IatroX, is more specific about where that risk concentrates: speech recognition may struggle with complex drug names, the system does not independently verify whether a prescribed medication is appropriate for the patient, and it does not assess whether a referral meets the receiving service's own criteria. None of that is disputed by Heidi -- the company's own published guidance says largely the same thing -- but it is a meaningfully different claim than "AI Care Partner" suggests on its own.

The $340 million buys Heidi runway to sell further into large health systems, not a change in what regulators have approved it to do. Co-founder and CEO Dr. Thomas Kelly framed the ambition beyond note-taking in the company's own announcement: "From the day I started Heidi, the ambition was always bigger than writing doctor's notes." (Heidi's roughly $430 million in total funding to date, and its jump from a $1-million to $50-million revenue run rate in two years, are the numbers investors are pricing -- not an independent measurement of clinical accuracy, which does not yet exist for either the scribing product or Evidence.) Whether that ambition extends into a formal decision-support product -- and what regulatory classification would then apply -- is the open question this round's capital is meant to help answer, not one it settles on its own.